 |
97 Diseases |  |
247 Trials |
|
247 Trials |  |
14602 News |  |
| «12...159160161162163164165166167168169170171» |
- |||| rivaroxaban / Generic mfg.
Trial completion: X-PLORER: Exploring the Efficacy and Safety of Rivaroxaban to Support Elective Percutaneous Coronary Intervention (clinicaltrials.gov) - Mar 20, 2013
P2, N=108, Completed, Sponsor: Bayer
Active, not recruiting --> Completed
- | New P4 trial: Investigation into the possibilities of finding antidotes for the new oral anti blood clotting agents Suche nach Medikamenten zur Umkehr der Wirkung der neuen oralen Antikoagulantien (NOACs) und neuen Blutplättchen-Hemmer (NOPAIs) (EUDRACT) - Mar 18, 2013
P4, N=120, Ongoing, Sponsor: Medizinische Universität Innsbruck / Univ.-Klinik für Allg. u. Chirurg. Intensivmedizin
- | New P4 trial, Combination therapy: Antithrombotic Triple Therapy in Humans (clinicaltrials.gov) - Mar 14, 2013
P4, N=60, Completed, Sponsor: Medical University of Vienna
- rivaroxaban / Generic mfg.
Trial initiation date: RivaMoS2: Rivaroxaban Laboratory Monitoring in Switzerland 2: Therapeutic Dose (RivaMoS 2) (clinicaltrials.gov) - Mar 5, 2013
P=N/A, N=20, Recruiting, Sponsor: Prof. Dr. Dr. med. Walter A. Wuillemin, MD, PhD
Active, not recruiting --> Completed Initiation date: Nov 2012 --> Mar 2013
- rivaroxaban / Generic mfg.
Enrollment open: RivaMoS2: Rivaroxaban Laboratory Monitoring in Switzerland 2: Therapeutic Dose (RivaMoS 2) (clinicaltrials.gov) - Mar 5, 2013
P=N/A, N=20, Recruiting, Sponsor: Prof. Dr. Dr. med. Walter A. Wuillemin, MD, PhD
Initiation date: Nov 2012 --> Mar 2013 Not yet recruiting --> Recruiting
- | Xarelto (rivaroxaban) / J&J
Enrollment open: EINSTEINJunior: Oral Rivaroxaban in Children With Venous Thrombosis (clinicaltrials.gov) - Feb 21, 2013
P2, N=50, Recruiting, Sponsor: Bayer
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || Fragmin (dalteparin sodium) / Pfizer, Eisai
New P3 trial: Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism (EUDRACT) - Feb 17, 2013
P3, N=530, Ongoing, Sponsor: University of Warwick
- |||||| rivaroxaban / Generic mfg.
Enrollment open: VENTURE-AF: A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy (clinicaltrials.gov) - Feb 8, 2013
P3, N=200, Recruiting, Sponsor: Janssen Scientific Affairs, LLC
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| rivaroxaban / Generic mfg., dabigatran etexilate / Generic mfg., apixaban / Generic mfg.
Trial initiation date, Surgery: BRUISECONTROL2: Strategy of Continued Versus Interrupted Novel Oral Anti-coagulant at Time of Device Surgery in Patients With Moderate to High Risk of Arterial Thromboembolic Events (clinicaltrials.gov) - Feb 3, 2013
P3, N=846, Recruiting, Sponsor: University of Ottawa Heart Institute
Not yet recruiting --> Recruiting Initiation date: Oct 2012 --> Jan 2013
- | rivaroxaban / Generic mfg., aspirin / Generic mfg.
Enrollment open: EPCAT II: Extended Venous Thromboembolism Prophylaxis Comparing Rivaroxaban to Aspirin Following Total Hip and Knee Arthroplasty (clinicaltrials.gov) - Feb 3, 2013
P3, N=3426, Recruiting, Sponsor: David Anderson
Initiation date: Oct 2012 --> Jan 2013 Not yet recruiting --> Recruiting
- |||||| rivaroxaban / Generic mfg., dabigatran etexilate / Generic mfg., apixaban / Generic mfg.
Enrollment open, Surgery: BRUISECONTROL2: Strategy of Continued Versus Interrupted Novel Oral Anti-coagulant at Time of Device Surgery in Patients With Moderate to High Risk of Arterial Thromboembolic Events (clinicaltrials.gov) - Feb 3, 2013
P3, N=846, Recruiting, Sponsor: University of Ottawa Heart Institute
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||||| rivaroxaban / Generic mfg.
New P3 trial: COMPASS: Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease (clinicaltrials.gov) - Jan 24, 2013
P3, N=19500, Recruiting, Sponsor: Bayer
- | rivaroxaban / Generic mfg.
Trial initiation date: Rivaroxaban for Treatment of Patients With Suspected or Confirmed Heparin-Induced Thrombocytopenia (clinicaltrials.gov) - Jan 20, 2013
P3, N=200, Recruiting, Sponsor: McMaster University
Not yet recruiting --> Recruiting Initiation date: Jun 2012 --> Jan 2013
- | rivaroxaban / Generic mfg.
Enrollment open: Rivaroxaban for Treatment of Patients With Suspected or Confirmed Heparin-Induced Thrombocytopenia (clinicaltrials.gov) - Jan 20, 2013
P3, N=200, Recruiting, Sponsor: McMaster University
Initiation date: Jun 2012 --> Jan 2013 Not yet recruiting --> Recruiting
- ||| rivaroxaban / Generic mfg.
Enrollment open: XANAP: Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Asia (clinicaltrials.gov) - Jan 9, 2013
P=N/A, N=2300, Recruiting, Sponsor: Bayer
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | rivaroxaban / Generic mfg.
New P4 trial: Anticoagulation With Rivaroxaban in Cardioversion -The ARC Study (clinicaltrials.gov) - Dec 10, 2012
P4, N=60, Recruiting, Sponsor: John H. Stroger Hospital
- |||||||||| rivaroxaban / Generic mfg.
New P3 trial: VENTURE-AF: A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy (clinicaltrials.gov) - Nov 18, 2012
P3, N=200, Recruiting, Sponsor: Janssen Scientific Affairs, LLC
- |||| Enrollment open: Rhythm Evaluation for AntiCoagulaTion With COntinuous Monitoring (clinicaltrials.gov) - Nov 12, 2012
P4, N=75, Recruiting, Sponsor: Northwestern University
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- rivaroxaban / Generic mfg.
New P2 trial: Proof of concept, multicenter trial with Rivaroxaban in the treatment of livedoid vasculopathy assessing the pain on a visual analog scale (VAS) (EUDRACT) - Nov 8, 2012
P2, N=20, Ongoing, Sponsor: Universitätsklinikum Münster
- || rivaroxaban / Generic mfg., aspirin / Generic mfg.
New P3 trial: EPCAT II: Extended Venous Thromboembolism Prophylaxis Comparing Rivaroxaban to Aspirin Following Total Hip and Knee Arthroplasty (clinicaltrials.gov) - Oct 31, 2012
P3, N=3426, Recruiting, Sponsor: David Anderson
- rivaroxaban / Generic mfg.
Trial completion: Ex-vivo Effect of New Oral Anticoagulants on Point-of-care Devices (clinicaltrials.gov) - Oct 31, 2012
P=N/A, N=100, Completed, Sponsor: Johann Wolfgang Goethe University Hospitals
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- || rivaroxaban / Generic mfg.
Trial initiation date: XALIA: Treatment of an Acute Deep Vein Thrombosis (DVT) With Either Rivaroxaban or Current Standard of Care Therapy (clinicaltrials.gov) - Oct 16, 2012
P=N/A, N=4800, Active, not recruiting, Sponsor: Bayer
Active, not recruiting --> Completed Initiation date: Jan 2012 --> Jun 2012
- || rivaroxaban / Generic mfg.
Trial initiation date: XANTUS: Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation (clinicaltrials.gov) - Oct 16, 2012
P=N/A, N=6000, Active, not recruiting, Sponsor: Bayer
Initiation date: Jan 2012 --> Jun 2012 Initiation date: Jan 2012 --> Jun 2012
- | rivaroxaban / Generic mfg.
New P4 trial: Study in Cancer Patients With Central Line Associated Clots in the Upper Extremity Treated With Rivaroxaban (Catheter 2) (clinicaltrials.gov) - Oct 15, 2012
P4, N=72, Not yet recruiting, Sponsor: London Health Sciences Centre
- ||||| New P4 trial: Rhythm Evaluation for AntiCoagulaTion With COntinuous Monitoring (clinicaltrials.gov) - Oct 11, 2012
P4, N=75, Recruiting, Sponsor: Northwestern University
- rivaroxaban / Generic mfg., dabigatran etexilate / Generic mfg.
Enrollment open, Preclinical: Effect of New Oral Anticoagulants Dabigatran and Rivaroxaban on Point of Care Coagulation Testing - an Ex-Vivo Study (clinicaltrials.gov) - Oct 9, 2012
P=N/A, N=34, Recruiting, Sponsor: Johann Wolfgang Goethe University Hospitals
Initiation date: Jan 2012 --> Jun 2012 Not yet recruiting --> Recruiting
- | rivaroxaban / Generic mfg., warfarin / Generic mfg.
New P2 trial: Comparison of rivaroxaban (Xarelto (EUDRACT) - Oct 7, 2012
P2, N=156, Ongoing, Sponsor: University College London
- | Xarelto (rivaroxaban) / J&J
New P2 trial: EINSTEINJunior: Oral Rivaroxaban in Children With Venous Thrombosis (clinicaltrials.gov) - Sep 11, 2012
P2, N=50, Recruiting, Sponsor: Bayer
- | rivaroxaban / Generic mfg.
Trial completion: A Study to Assess the Effects of 2 Different Prothrombin Complex Concentrates on the Pharmacodynamics of Rivaroxaban in Healthy Adult Volunteers (clinicaltrials.gov) - Sep 11, 2012
P1, N=35, Completed, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Recruiting Recruiting --> Completed
- |||||||||| rivaroxaban / Generic mfg., dabigatran etexilate / Generic mfg., apixaban / Generic mfg.
New P3 trial, Surgery: BRUISECONTROL2: Strategy of Continued Versus Interrupted Novel Oral Anti-coagulant at Time of Device Surgery in Patients With Moderate to High Risk of Arterial Thromboembolic Events (clinicaltrials.gov) - Aug 27, 2012
P3, N=846, Recruiting, Sponsor: University of Ottawa Heart Institute
- |||||||||| rivaroxaban / Generic mfg.
New P3 trial: X-VERT: Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion (clinicaltrials.gov) - Aug 27, 2012
P3, N=1504, Completed, Sponsor: Bayer
- |||| TB-402 / Y's Therap
Trial completion, Surgery: Single IV Administration of TB-402 for Prophylaxis of Venous Thromboembolic Events (VTE) After Total Hip Replacement Surgery (clinicaltrials.gov) - Aug 21, 2012
P2, N=632, Completed, Sponsor: ThromboGenics
Recruiting --> Completed Active, not recruiting --> Completed
- | rivaroxaban / Generic mfg.
New P1 trial: A Study to Assess the Effects of 2 Different Prothrombin Complex Concentrates on the Pharmacodynamics of Rivaroxaban in Healthy Adult Volunteers (clinicaltrials.gov) - Aug 1, 2012
P1, N=35, Completed, Sponsor: Janssen Research & Development, LLC
- ||| rivaroxaban / Generic mfg.
Enrollment open: Xarelto [SPAF-QOL] Post-marketing Surveillance in Japan (clinicaltrials.gov) - Jun 27, 2012
P=N/A, N=725, Recruiting, Sponsor: Bayer
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | rivaroxaban / Generic mfg.
New P2 trial: ERIKA: Efficacy of RIvaroxaban for Prevention of Venous Thromboembolism After Knee Arthroscopy (clinicaltrials.gov) - Jun 25, 2012
P2, N=500, Recruiting, Sponsor: University of Padua
- || rivaroxaban / Generic mfg., dabigatran etexilate / Generic mfg.
Biomarker, New P2/3 trial: Pharmacogenomic Study on PKD/PKC of Dabigatran Etexilate and Rivaroxaban (clinicaltrials.gov) - Jun 24, 2012
P2/3, N=60, Recruiting, Sponsor: Assistance Publique - H
- | rivaroxaban / Generic mfg., warfarin / Generic mfg.
Trial completion: A Study to Explore the Pharmacodynamic Changes When Transitioning From Rivaroxaban to Warfarin in Healthy Volunteers (clinicaltrials.gov) - Jun 4, 2012
P1, N=46, Completed, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||||||| rivaroxaban / Generic mfg.
Trial completion: An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome (clinicaltrials.gov) - May 20, 2012
P3, N=15526, Completed, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| rivaroxaban / Generic mfg.
Enrollment open: XAPASS: Xarelto [SPAF] Post-marketing Surveillance in Japan (clinicaltrials.gov) - May 17, 2012
P=N/A, N=10000, Recruiting, Sponsor: Bayer
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- || rivaroxaban / Generic mfg.
New P3 trial: Rivaroxaban for Treatment of Patients With Suspected or Confirmed Heparin-Induced Thrombocytopenia (clinicaltrials.gov) - May 13, 2012
P3, N=200, Recruiting, Sponsor: McMaster University
- |||||| Xarelto (rivaroxaban) / J&J, fondaparinux / Generic mfg.
Enrollment open: SURPRISE-2011: Superficial Vein Thrombosis (SVT) Treated With Rivaroxaban Versus Fondaparinux (clinicaltrials.gov) - Apr 25, 2012
P3, N=506, Recruiting, Sponsor: GWT-TUD GmbH
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- rivaroxaban / Generic mfg., erythromycin / Generic mfg.
Enrollment change: A Study of Erythromycin and Rivaroxaban in Study Participants With Normal and Reduced Kidney Function (clinicaltrials.gov) - Apr 18, 2012
P1, N=29, Completed, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Recruiting N=24 --> 29
- | rivaroxaban / Generic mfg., erythromycin / Generic mfg.
Trial completion: A Study of Erythromycin and Rivaroxaban in Study Participants With Normal and Reduced Kidney Function (clinicaltrials.gov) - Apr 18, 2012
P1, N=29, Completed, Sponsor: Janssen Research & Development, LLC
N=24 --> 29 Recruiting --> Completed
- rivaroxaban / Generic mfg., warfarin / Generic mfg.
Enrollment change: A Study to Explore the Pharmacodynamic Changes When Transitioning From Rivaroxaban to Warfarin in Healthy Volunteers (clinicaltrials.gov) - Apr 5, 2012
P1, N=46, Completed, Sponsor: Janssen Research & Development, LLC
Recruiting --> Completed N=34 --> 46
- ||| rivaroxaban / Generic mfg.
Trial completion: Pharmacokinetics Study of Oral Rivaroxaban in Healthy Participants (clinicaltrials.gov) - Mar 28, 2012
P1, N=55, Completed, Sponsor: Janssen Scientific Affairs, LLC
N=34 --> 46 Active, not recruiting --> Completed
- rivaroxaban / Generic mfg., dabigatran etexilate / Generic mfg.
Enrollment open: REVANT: Reversal of the Antithrombotic Action of New Oral Anticoagulants (clinicaltrials.gov) - Mar 8, 2012
P4, N=10, Recruiting, Sponsor: Gines Escolar
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- rivaroxaban / Generic mfg., dabigatran etexilate / Generic mfg.
Biomarker, Trial completion: A Study to Investigate Biomarkers After Single Doses of Anticoagulants in Healthy Young Male and Healthy Elderly Participants (MK-0000-216 AM1) (clinicaltrials.gov) - Feb 19, 2012
P1, N=42, Completed, Sponsor: Merck
Not yet recruiting --> Recruiting Recruiting --> Completed
- |||||||||| rivaroxaban / Generic mfg.
New P3 trial: Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients (clinicaltrials.gov) - Jan 23, 2012
P3, N=60, Completed, Sponsor: Bayer
- ||| rivaroxaban / Generic mfg.
New P3 trial: Venous Thromboembolism (VTE) Treatment Study in Japanese Pulmonary Embolism (PE) Patients (clinicaltrials.gov) - Jan 23, 2012
P3, N=40, Completed, Sponsor: Bayer
- ||| Xarelto (rivaroxaban) / J&J, warfarin / Generic mfg.
New P1 trial: Switching Study From Warfarin to Rivaroxaban (clinicaltrials.gov) - Jan 8, 2012
P1, N=96, Completed, Sponsor: Bayer